These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35703246)

  • 1. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
    Agoro R; White KE
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
    Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
    J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
    Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
    Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia.
    Czaya B; Faul C
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
    Courbon G; Martinez-Calle M; David V
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
    Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-renal-Related Mechanisms of FGF23 Pathophysiology.
    Hanudel MR; Laster M; Salusky IB
    Curr Osteoporos Rep; 2018 Dec; 16(6):724-729. PubMed ID: 30353318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
    Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
    Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
    Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
    Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23.
    Ikeda Y
    Kidney Int; 2021 Jul; 100(1):14-16. PubMed ID: 34154707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
    Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
    Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
    Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
    Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia.
    Agoro R; Montagna A; Goetz R; Aligbe O; Singh G; Coe LM; Mohammadi M; Rivella S; Sitara D
    FASEB J; 2018 Jul; 32(7):3752-3764. PubMed ID: 29481308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia.
    Figurek A; Rroji M; Spasovski G
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
    Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review).
    Zhang R; Wang SY; Yang F; Ma S; Lu X; Kan C; Zhang JB
    Exp Ther Med; 2021 Oct; 22(4):1159. PubMed ID: 34504604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.